Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: EN Paris
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

TNG:FP

4.9700 EUR 0.0500 1.02%

As of 11:35:00 ET on 05/22/2015.

Snapshot for Transgene SA (TNG)

Open: 4.9300 Day's Range: 4.9200 - 5.0300 Volume: 80,138
Previous Close: 4.9200 52wk Range: 4.9000 - 10.7300 1-Yr Rtn: -44.22%

Stock Chart for TNG

No chart data available.
  • TNG:FP 4.9700
  • 1D
  • 1M
  • 1Y
4.9200
Interactive TNG Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for TNG

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. CAC -
Earnings Per Share (EUR) (ttm) -1.2600
Est. EPS (EUR) (12/2015) -1.3780
Est. PEG Ratio -
Market Cap (M EUR) 191.47
Shares Outstanding (M) 38.53
30 Day Average Volume 87,147
Price/Book (mrq) 2.6655
Price/Sale (ttm) 76.8149
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 09/10/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for TNG

  • Revenue
  • Net Income (M/EUR)
  • Profit Margin (%)

Company Profile & Key Executives for TNG

Transgene S.A. is a biotechnology company. The Company develops vaccines against cancer and infectious diseases. Transgene has products under development for lung, kidney, prostate and colorectal cancers, cutaneous T-cell lymphoma, hepatitis C, malignant melanoma, and muscular dystrophy.

Philippe ArchinardChairman/CEOEric QuemeneurExec VP/VP:Research & Dev
Nathalie AddaDir:Regulatory AffairsPatrick MahieuxDir:Industrial Operations
More Company Profile & Key Executives for TNG

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil